Payment overview · 2025
General Payments
$9,365.26
136 reported records · 30 companies
Healthcare provider profile · identity verified
Vinod Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BROOKLYN, NY · NPI 1609814490
Verified facts
What the public records show
CMS Open Payments records show Vinod Patel, MD received $9,365.26 in general payments during 2025 across 136 reported records.
SCPHARMACEUTICALS INC. accounted for 54.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Furoscix, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 545 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 545 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
SCPHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FUROSCIX as an associated drug or biological on 18968 records involving 9678 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Furoscix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $5,123.15 | 54.7% | 6 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $830.28 | 8.9% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $575.19 | 6.1% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $323.82 | 3.5% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $280.63 | 3.0% | 13 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $227.39 | 2.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.99 | 1.9% | 9 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $171.69 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.08 | 1.6% | 8 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $142.41 | 1.5% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $140.36 | 1.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $120.09 | 1.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.29 | 1.2% | 5 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $104.98 | 1.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $95.48 | 1.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.84 | 1.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.28 | 0.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.48 | 0.9% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $80.23 | 0.9% | 4 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $72.54 | 0.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $65.81 | 0.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.22 | 0.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.48 | 0.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.95 | 0.5% | 2 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $27.70 | 0.3% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $27.53 | 0.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $26.20 | 0.3% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $22.07 | 0.2% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.90 | 0.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.20 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Honoraria | $4,800.00 | 2 |
| Food and Beverage | $4,426.38 | 131 |
| Education | $100.21 | 2 |
| Travel and Lodging | $38.67 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $5,123.15 | 6 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $830.28 | 14 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $323.82 | 23 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $289.46 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $175.99 | 9 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $174.39 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $171.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.38 | 8 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $142.41 | 1 | 2025 |
Source payment records
|
|||||
| ABSOLUTE PRO Normalized: absolute pro |
Device | Abbott Laboratories | $140.73 | 1 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $140.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $127.25 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $126.90 | 7 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $120.09 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.29 | 5 | 2025 |
Source payment records
|
|||||
| EMBOSHIELD NAV6 Normalized: emboshield nav6 |
Device | Abbott Laboratories | $105.27 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $104.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.17 | 6 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $95.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $91.84 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $91.84 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $83.48 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.48 | 4 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $80.23 | 4 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $79.99 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $72.54 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $65.81 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $61.10 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.48 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.95 | 2 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $40.15 | 1 | 2025 |
Source payment records
|
|||||
| OMNILINK ELITE Normalized: omnilink elite |
Device | Abbott Laboratories | $39.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.25 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.97 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| Holter Normalized: holter |
Device | Philips North America LLC | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $12.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 200 | exact normalized | Medicare Part D |
| FUROSCIX furoscix |
2025 | Furoscix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 545 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 117 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 198 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
147 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
545 | 164 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
545 | 164 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
117 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
128 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
198 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 59 |
| SCPHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | FUROSCIX open payments reported associated product |
CMS Open Payments — General Payments 18968 supporting records · 9678 recipient NPIs · example record 1228171755 |
Furoscix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1213 | 414 |
| Metoprolol Succinate | Metoprolol Succinate | 858 | 304 |
| Amlodipine Besylate | Amlodipine Besylate | 645 | 240 |
| Jardiance | Empagliflozin | 545 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 452 | 194 |
| Nifedipine Er | Nifedipine | 371 | 119 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 355 | 114 |
| Metformin Hcl | Metformin Hcl | 346 | 112 |
| Gabapentin | Gabapentin | 318 | 125 |
| Losartan Potassium | Losartan Potassium | 269 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 92 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 130 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 74 |
| Furosemide | Furosemide | 223 | 88 |
| Eliquis | Apixaban | 200 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 55 |
| Ozempic | Semaglutide | 198 | 42 |
| Simvastatin | Simvastatin | 190 | 65 |
| Montelukast Sodium | Montelukast Sodium | 176 | 92 |
| Carvedilol | Carvedilol | 172 | 57 |
| Cilostazol | Cilostazol | 167 | 92 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 161 | 47 |
| Farxiga | Dapagliflozin Propanediol | 147 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 73 |
| Azithromycin | Azithromycin | 137 | 113 |
| Omeprazole | Omeprazole | 132 | 51 |
| Xarelto | Rivaroxaban | 132 | 35 |
| Entresto | Sacubitril/Valsartan | 128 | 36 |
| Mounjaro | Tirzepatide | 117 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 114 | 37 |
| Spironolactone | Spironolactone | 114 | 41 |
| Labetalol Hcl | Labetalol Hcl | 108 | 30 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 103 | 34 |
| Famotidine | Famotidine | 101 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 38 |
| Meclizine Hcl | Meclizine Hcl | 92 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 31 |
| Meloxicam | Meloxicam | 78 | 38 |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 27 |
| Prednisone | Prednisone | 77 | 60 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 65 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 56 |
| Nitroglycerin | Nitroglycerin | 61 | 31 |
| Sertraline Hcl | Sertraline Hcl | 60 | 21 |
| Finasteride | Finasteride | 58 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 18 |
| Lactulose | Lactulose | 55 | 26 |
| Allopurinol | Allopurinol | 54 | 19 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 52 | 22 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 19 |
| Synthroid | Levothyroxine Sodium | 44 | 16 |
| Enalapril Maleate | Enalapril Maleate | 43 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 23 |
| Glimepiride | Glimepiride | 41 | 12 |
| Ranolazine Er | Ranolazine | 41 | 13 |
| Alprazolam | Alprazolam | 40 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Lisinopril | Lisinopril | 39 | 18 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 11 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Clonidine | Clonidine | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 34 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 13 |
| Azelastine Hcl | Azelastine Hcl | 33 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | 11 |
| Fluconazole | Fluconazole | 30 | 28 |
| Torsemide | Torsemide | 30 | 11 |
| Diltiazem 12hr Er | Diltiazem Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 12 |
| Repatha Pushtronex | Evolocumab | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Furoscix | Furosemide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,365.26 · 136 records | SCPHARMACEUTICALS INC. | ABSOLUTE PRO, AIRSUPRA, AMS 700, AMVUTTRA, AREXVY, AVEIR, AVVIGO Guidance System, Acticor 7 VR-T DX, Assure WCD, Attruby, BREZTRI, CAMZYOS, Cologuard Collection Kit, ELIQUIS, EMBOSHIELD NAV6, FFRct, FUROSCIX, Flexitouch Plus, Holter, JARDIANCE, Kerendia, Korlym, LEQVIO, LIMFLOW SYSTEM, LifeVest, MOUNJARO, NURTEC ODT, Nimbl, OMNILINK ELITE, OPSUMIT, Ozempic, Paradise Ultrasound Renal Denervation System, REPATHA, RHYTHM EXPRESS, Rybelsus, SHINGRIX, TELEPATCH CARDIAC MONITOR, The Cologuard Plus Collection Kit, UPTRAVI, VERQUVO, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error